# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the ...
Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $...
B. Riley Securities analyst Kalpit Patel maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price t...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...
Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treat...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...
Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $...
Wedbush analyst Laura Chico maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target ...
Longboard Pharmaceuticals (NASDAQ:LBPH) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimat...